



For Information on Reimbursement and Patient Assistance Services, call the FOCUS ON ACCESS™ Hotline,

(866) 272-8838

Monday-Friday, 9 AM to 5 PM EST


XIPERE[®]
(triamcinolone acetonide
injectable suspension) 40 mg/mL
www.xipere.com


Visudyne[®]
verteporfin for injection
www.visudyne.com

Retisert[®]
(fluocinolone acetonide
intravitreal implant) 0.59 mg
www.retisert.com

Welcome to the FOCUS ON ACCESS™ (FOA) Program

FOA helps eligible patients secure access to the following products*:

- **XIPERE®** (triamcinolone acetonide injectable suspension) 40 mg/mL
- **VISUDYNE®** (verteporfin for injection)
- **RETISERT®** (fluocinolone acetonide intravitreal implant) 0.59 mg

Upon request, FOA offers the following services to patients*:

Reimbursement Support

- Investigate insurance coverage availability for the product prescribed (terms and conditions apply)
- Provide information about prior authorization, claim denials and appeals processes

Patient Assistance

- Subject to eligibility and program requirements, patients may be considered for the Patient Assistance Program if they don't have insurance or the product prescribed is not covered by their insurance plan

Bausch + Lomb, Focus on Access and Retisert are trademarks of Bausch & Lomb Incorporated or its affiliates.

XIPERE® is a trademark of Clearside Biomedical, Inc. used under license.

Visudyne is a registered trademark of Cheplapharm Arzneimittel GmbH used under license.

*Terms and conditions apply.

BAUSCH + LOMB

©2022 Bausch & Lomb Incorporated or its affiliates.

VID.0007.USA.22